Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Myelodysplastic Syndromes 19Lymphoma, Non-Hodgkin 17Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Graft vs Host Disease 13Lymphoma, Mantle-Cell 12Leukemia 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Sarcoma 10Lymphoma 10Lymphoma, Follicular 9Lymphoma, B-Cell, Marginal Zone 9Burkitt Lymphoma 9Myeloproliferative Disorders 8Waldenstrom Macroglobulinemia 7Tuberous Sclerosis 7Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Hematologic Neoplasms 7Congenital Abnormalities 7Primary Myelofibrosis 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myeloid, Accelerated Phase 6Breast Neoplasms 6Osteosarcoma 5

Interventions

sargramostim 3dinutuximab 3Colony-Stimulating Factors 3Temozolomide 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Isotretinoin 2Irinotecan 2temsirolimus 1Vincristine 1Topotecan 1Thiotepa 1Stem Cell Transplantation 1Sirolimus 1Razoxane 1Radiation 1Platinum 1Melphalan 1Etoposide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Congresses as Topic 1Cisplatin 1Carboplatin 1Biopsy 13-fluorobenzylguanidine 13-Iodobenzylguanidine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ganglioneuroblastoma × Sirolimus × Clear all
NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡